Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Vivus, Inc.
Total ban on background music is unnecessary, agency says in denying KEI’s petition. FDA points to new ‘major statement’ rule and its previous letters objecting to a sponsor’s use of music in ads and says it will continue case by case analysis of ‘all of the elements’ in an ad.
But the Centers for Medicare and Medicaid Services wants to see data first on how promoting coverage of the new obesity drugs would impact uptake, plan costs and beneficiary premiums.
Zydus is still on the lookout for deals post the recent acquisition of UK-based LiqMeds group as it sets a $100m sales target from specialty/rare disease products. Meanwhile, US revenues are seen stabilizing with new launches, even as lack of generic Revlimid sales in Q2 led to a 24% drop over the previous quarter.
Herbalife’s five sales regions leaving behind pandemic impact at different speeds; Abbott’s 15.5% nutritional sales growth didn’t overcome more than 30% slump in diagnostics sales; ChromaDex steady sales growth for most of past three years continues with 14% in latest quarter; USANA and Mannatech results slump.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.